CN Patent

CN104650171A — 索氟布韦倍半水合物化合物

Assigned to Tianjin Hankang Pharmaceutical Biotechnology Co Ltd · Expires 2015-05-27 · 11y expired

What this patent protects

本发明属于医药技术领域，具体涉及索氟布韦晶体及其制备方法，本发明得到的索氟布韦晶体，具有的优点：纯度高；稳定性好，即使在高湿度条件下吸湿增重也不明显。这一化合物是RNA-依赖性5RNA病毒复制的抑制剂，并且可用作HCVNS5B聚合酶的抑制剂、HCV复制的抑制剂、以及用于在哺乳动物中治疗丙型肝炎感染。

USPTO Abstract

本发明属于医药技术领域，具体涉及索氟布韦晶体及其制备方法，本发明得到的索氟布韦晶体，具有的优点：纯度高；稳定性好，即使在高湿度条件下吸湿增重也不明显。这一化合物是RNA-依赖性5RNA病毒复制的抑制剂，并且可用作HCVNS5B聚合酶的抑制剂、HCV复制的抑制剂、以及用于在哺乳动物中治疗丙型肝炎感染。

Drugs covered by this patent

Patent Metadata

Patent number: CN104650171A
Jurisdiction: CN
Classification: —
Expires: 2015-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Tianjin Hankang Pharmaceutical Biotechnology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.